Abstracts tagged "Disease Activity"

Abstract Number: 2547 • 2014 ACR/ARHP Annual Meeting
The Impact of Primary Sjögren’s Syndrome on Female Sexual Function
Jolien F. van Nimwegen¹, Suzanne Arends¹, Greetje S. van Zuiden¹, Arjan Vissink², Frans G.M. Kroese¹ and Hendrika Bootsma¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose . Primary Sjögren's syndrome (pSS) is a chronic and disabling disease, characterized by sicca symptoms of the eyes and mouth as well as fatigue.…
Abstract Number: 2135 • 2014 ACR/ARHP Annual Meeting
Patients with Moderate Disease Activity in the First 5 Years of Rheumatoid Arthritis Still Progress Radiographically Despite Conventional Disease Modifying Therapy
Lewis Carpenter¹, Elena Nikiphorou², Sam Norton³, Keeranur Jayakumar⁴, Josh Dixey⁵ and Adam Young⁶, ¹Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ²School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ³Institute of Psychiatry, King's College London, London, United Kingdom, ⁴Rheumatology, Heart of England NHS Foundation Trust, Birmingham, United Kingdom, ⁵Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁶Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: Patients with moderate disease are an important, and often poorly studied, patient subgroup. The extent to which traditional DMARD therapies adequately control the disease…
Abstract Number: 1593 • 2014 ACR/ARHP Annual Meeting
Neutrophil-Lymphocyte Ratio As a Marker of Disease Activity in Psoriatic Arthritis
Vinod Chandran¹, Arane Thavaneswaran² and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. There are few biomarkers for disease activity in PsA. Traditional acute phase reactants are…
Abstract Number: 1314 • 2014 ACR/ARHP Annual Meeting
Comparison of the Utility and Validity of Three Scoring Tools to Detect Skin Disease in Patients with Juvenile Dermatomyositis
Raquel Campanilho-Marques¹, Beverley Almeida², Katie Arnold¹, Kiran Nistala³, Clarissa A Pilkington⁴ and Lucy R Wedderburn¹, ¹Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ²Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ³Centre for Rheumatology, University College London, London, United Kingdom, ⁴Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare condition affecting 3 children/million/year. Muscle and skin involvement are key features. The muscle symptoms are frequently the main…
Abstract Number: 838 • 2014 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis Disease Activity on Cardiovascular Disease Risk: What Is the Role of the Flare?
Elena Myasoedova¹, Arun K. Chandran², Birkan İlhan³, Brittny T. Major⁴, C. John Michet III², Eric L. Matteson² and Cynthia S. Crowson⁴, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). Longitudinal studies assessing the effect of changes of RA activity on…
Abstract Number: 488 • 2014 ACR/ARHP Annual Meeting
Increases in Serum Cholesterol with Baricitinib Treatment Are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis
Joel M. Kremer¹, Mark C Genovese², Edward C. Keystone³, Peter C. Taylor⁴, Steven H. Zuckerman⁵, Douglas E. Schlichting⁵, Eric P. Nantz⁵, Scott D. Beattie⁵ and William L. Macias⁶, ¹Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ²Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³University of Toronto, Toronto, ON, Canada, ⁴NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Treatment with baricitinib (bari), an oral inhibitor of JAK1/JAK2, demonstrated improvements in signs and symptoms of RA through 52 wks in a Phase 2b…
Abstract Number: 356 • 2014 ACR/ARHP Annual Meeting
The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis
Lena Bugge Nordberg¹, Elisabeth Lie², Anna-Birgitte Aga¹, Marthe Thoresen Maehlen³, Inge Olsen C⁴, Till Uhlig⁴, Tore K. Kvien⁴, Espen A. Haavardsholm⁵ and the Arctic study Group⁵, ¹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The Rheumatoid arthritis impact of disease (RAID) score is a relatively new patient-derived composite score assessing the seven most important domains of the impact…
Abstract Number: 2913 • 2014 ACR/ARHP Annual Meeting
Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Nazim Reshiti², Toni Kaegi³, Axel Finckh⁴, Hendrik Schulze-Koops⁵, Michael H. Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, St. Gallen, Switzerland, ³Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ⁶School of Medicine, University of Colorado, Denver, CO, ⁷Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose Anti-inflammatory and disease-modifying properties of glucocorticoids (GCs) have been demonstrated in patients with rheumatoid arthritis (RA). Better outcomes in trials by combinations of synthetic…
Abstract Number: 2518 • 2014 ACR/ARHP Annual Meeting
What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?
Edward C. Keystone¹, Philip Baer², J. Antonio Avina-Zubieta³, Anna Jaroszynska⁴, Jude Rodrigues⁵, Regan Arendse⁶, Dalton Sholter⁷, Michael Starr⁸, Ariel Masetto⁹, John S. Sampalis¹⁰, Emmanouil Rampakakis¹⁰, Francois Nantel¹¹, May Shawi¹¹, Allen J Lehman¹² and Susan Otawa¹², ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Private Practice, Scarborough, ON, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Burlington, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁹Rheumatology, CHUS, Fleurimont, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Several standardized response criteria and disease activity indices are used to assess treatment efficacy in rheumatoid arthritis (RA). These measures comprise different types and…
Abstract Number: 2145 • 2014 ACR/ARHP Annual Meeting
Diagnostic Performance and Disease Activity Assessment By FDG-PET in Large-Vessel Vasculitis: A Systematic Literature Review and Meta-Analysis
Michael Soussan¹, Patrick Nicolas², Catherine Schramm³, Sandrine Katsahian³, Veronique Eder⁴, Olivier Fain⁵ and Arsene Mekinian⁶, ¹Nuclear Medicine, Avicennes Hospital, Bobigny, France, ²Pharmacology, Avicenne Hospital, 93000, France, ³Inserm U1138, Centre de Recherche des Cordeliers, Equipe 22, Paris 5, Paris 6, Paris, France, paris, France, ⁴Nuclear Medicine, Avicenne Hospital, Bobigny, France, ⁵Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ⁶Internal Medicine, DHUi2B Saint Antoine Hospital, paris, France
Background/Purpose: FDG-PET is increasingly used in the work up of large-vessel vasculitis (LVV). The purpose of this study is to perform a systematic review and…
Abstract Number: 1584 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Patient Acceptable Symptom State in Patients with Psoriatic Arthritis
Pinar Cetin¹, Dilek Solmaz², Murat Keser³, Ismail Sari¹, Merih Birlik¹, Nurullah Akkoc¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Namik Kemal University School of Medicine, Tekirdag, Turkey, ³Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
Background/Purpose The Patient Acceptable Symptom State (PASS), a single-question outcome, has been defined as an absolute level of patient well-being, which was used in the…
Abstract Number: 1238 • 2014 ACR/ARHP Annual Meeting
Proportion of Peripheral Plasmacytoid Dendritic Cells and Plasmablasts Reflects Disease Activity in IgG4-related Disease
Mitsuhiro Akiyama¹, Katsuya Suzuki¹, Yoshiaki Kassai², Takahiro Miyazaki², Rimpei Morita³, Akihiko Yoshimura³ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ³Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a recently recognized fibro-inflammatory disease with multi-organ system involvement. Affected patients frequently have a history of bronchial asthma and allergic rhinitis. The reported pathogenesis of IgG4-RD describes the clear involvement of excessive Th2 cells and regulatory immune reaction in addition to plasma cells 1). However, peripheral immune cell phenotype, which reflects disease status, has not been comprehensively evaluated. Our aim was to definitively determine peripheral blood cell abnormalities and their correlation with disease activity in patients with IgG4-RD.Methods Peripheral blood samples were obtained from active untreated IgG4-RD patients (n=11) and healthy controls (n=16). Comprehensive immunophenotyping assay with information on activation status was done by multi-color flow cytometry, and the proportion of peripheral blood mononuclear cells (PBMCs), including T cells (naïve/memory, Th1/2/17, Treg, and Tfh), B cells (naïve/memory, plasmablast, Breg), monocytes (classical, intermediate, non-classical) and dendritic cells (myeloid, plasmacytoid), and their activity status were precisely defined. Disease activity was measured using the IgG4-RD responder index (RI). Statistical analysis was done using the Mann-Whitney U test and Spearman rank correlation coefficient test.Results The proportion of plasmablasts (CD19+CD20-CD27+CD38+), memory Th2 cells (CD3+CD4+CXCR3-CCR6-CD45RA-), Tregs (CD3+CD4+CD25+CD127low), Tfh (CD3+CD4+CXCR5+), and mDCs (CD3-CD19-CD14-HLA-DR+CD1c+CD303-) in peripheral blood was significantly increased in IgG4-RD patients compared with HC, whereas the proportion of pDCs (CD3-CD19-CD14-HLA-DR+CD1c-CD303+）was significantly decreased. Interestingly, the proportion of pDCs in total DCs was negatively correlated with IgG4-RD RI (r=-0.778, p=0.005) while the proportion of plasmablasts in CD19+cells was positively correlated with RI (r=0.701, p=0.016). Further, the increased proportion of plasmablasts was positively correlated with serum IgG4 level (r=0.718, p=0.013) while the decreased proportion of pDCs tended to be negatively correlated with the number of affected organs (r=-0.518, p=0.061). Conclusion Our comprehensive analysis identified distinct proportional changes in PBMCs in IgG4-RD. In particular, the decrease in pDCs and increase in plasmablasts were strongly linked with disease activity. These combined measurements are expected to be clinically useful surrogate cell markers. This newly identified decrease in circulating pDCs may be involved in the pathogenesis in IgG4-RD via the recently described role in the enhancement of Th2 response 2).References: 1) Stone JH et.al. N Engl J Med 2012;366:539-51 2) Maazi H et.al. Allergy 2013;68:695-701
Abstract Number: 720 • 2014 ACR/ARHP Annual Meeting
Measures of Disease Status in Systemic Sclerosis: Systematic Review
Tien Tay¹, Nava Ferdowsi¹, Wendy Stevens¹, Marie Hudson², Murray Baron³, Candice Rabusa¹, David Prior⁴, Susanna Proudman⁵ and Mandana Nikpour⁶, ¹Rheumatology, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Cardiology, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ⁵Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁶Medicine, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia
Background/Purpose : To identify the measures of disease status in systemic sclerosis (SSc) using a systematic review. Methods: A systematic review of Medline (1966-2014), EMBASE…
Abstract Number: 426 • 2014 ACR/ARHP Annual Meeting
Exploring the DAS: What Is the Level of Agreement in the Classification of Remission and Low Disease Activity (LDA) Among the Various Versions of the Disease Activity Score (DAS) and Their Correlation? an Analysis from a Prospective, Observational Registry
WG Bensen¹, Edward Keystone², Philip Baer³, Jude Rodrigues⁴, J. Antonio Avina-Zubieta⁵, Wojciech Olszynski⁶, Denis Choquette⁷, Suneil Kapur⁸, Manisha Mulgund⁹, John S. Sampalis¹⁰, Emmanouil Rampakakis¹⁰, Francois Nantel¹¹, Allen J Lehman¹², May Shawi¹¹ and Susan Otawa¹², ¹St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Private Practice, Scarborough, ON, Canada, ⁴Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁹Private Practice, Hamilton, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Two versions of DAS28 are available, DAS28-4 comprising 4 variables [tender and swollen joint counts, acute phase reactant (APR), and patient global assessment] and…
Abstract Number: 350 • 2014 ACR/ARHP Annual Meeting
Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies
Reena Khianey¹, Cristina Rozo², Sanjay Gupta³, Vivian P. Bykerk¹, Susan M. Goodman¹ and Alessandra B. Pernis⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²535 East 70th Street, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Research, Hospital for Special Surgery, New York, NY
Background/Purpose: Rho-associated protein kinases (ROCKs) regulate cytoskeletal reorganization and gene expression through protein phosphorylation, and are implicated in the pathogenesis of a wide range of…